RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Contrasting patterns of serologic and functional antibody dynamics to <i>Plasmodium falciparum</i> antigens in a Kenyan birth cohort
Dent, A. E., Malhotra, I., Wang, X., Babineau, D., Yeo, K. T., Anderson, T., Kimmel, R. J., Angov, E., Lanar, D. E., Narum, D., Dutta, S., Richards, J., Beeson, J. G., Crabb, B. S., Cowman, A. F., Horii, T., Muchiri, E., Mungai, P. L., King, C. L., & Kazura, J. W. (2016). Contrasting patterns of serologic and functional antibody dynamics to Plasmodium falciparum antigens in a Kenyan birth cohort. Clinical and Vaccine Immunology, 23(2), 104-116. https://doi.org/10.1128/CVI.00452-15
IgG antibodies to Plasmodium falciparum are transferred from the maternal to fetal circulation during pregnancy, wane after birth, and are subsequently acquired in response to natural infection. We examined the dynamics of malaria antibody responses of 84 Kenyan infants from birth to 36 months of age by (i) serology, (ii) variant surface antigen (VSA) assay, (iii) growth inhibitory activity (GIA), and (iv) invasion inhibition assays (IIA) specific for merozoite surface protein 1 (MSP1) and sialic acid-dependent invasion pathway. Maternal antibodies in each of these four categories were detected in cord blood and decreased to their lowest level by approximately 6 months of age. Serologic antibodies to 3 preerythrocytic and 10 blood-stage antigens subsequently increased, reaching peak prevalence by 36 months. In contrast, antibodies measured by VSA, GIA, and IIA remained low even up to 36 months. Infants sensitized to P. falciparum in utero, defined by cord blood lymphocyte recall responses to malaria antigens, acquired antimalarial antibodies at the same rate as those who were not sensitized in utero, indicating that fetal exposure to malaria antigens did not affect subsequent infant antimalarial responses. Infants with detectable serologic antibodies at 12 months of age had an increased risk of P. falciparum infection during the subsequent 24 months. We conclude that serologic measures of antimalarial antibodies in children 36 months of age or younger represent biomarkers of malaria exposure rather than protection and that functional antibodies develop after 36 months of age in this population.